Weizman A - Search Results

1

Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.

Poleg S, Golubchik P, Offen D, Weizman A. Poleg S, et al. Among authors: weizman a. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:90-96. doi: 10.1016/j.pnpbp.2018.08.030. Epub 2018 Aug 29. Prog Neuropsychopharmacol Biol Psychiatry. 2019. PMID: 30171992 Review.

2

Platelet benzodiazepine binding in Alzheimer's disease.

Bidder M, Ratzoni G, Weizman A, Blumensohn R, Norymberg M, Tyano S, Gavish M. Bidder M, et al. Among authors: weizman a. Biol Psychiatry. 1990 Oct 1;28(7):641-3. doi: 10.1016/0006-3223(90)90403-o. Biol Psychiatry. 1990. PMID: 2171687 No abstract available.

3

Up-regulatory effect of triphasic oral contraceptive on platelet 3H-imipramine binding sites.

Weizman A, Morgenstern H, Kaplan B, Amiri Z, Tyano S, Ovadia Y, Rehavi M. Weizman A, et al. Psychiatry Res. 1988 Jan;23(1):23-9. doi: 10.1016/0165-1781(88)90031-5. Psychiatry Res. 1988. PMID: 2834763

4

Platelets as neuronal models in neuropsychiatric disorders.

Rehavi M, Weizman R, Weizman A. Rehavi M, et al. Among authors: weizman r, weizman a. Prog Clin Biol Res. 1988;283:569-83. Prog Clin Biol Res. 1988. PMID: 3211960 No abstract available.

5

Cytokine production in drug-free and neuroleptic-treated schizophrenic patients.

Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A. Bessler H, et al. Among authors: weizman a. Biol Psychiatry. 1995 Sep 1;38(5):297-302. doi: 10.1016/0006-3223(94)00299-I. Biol Psychiatry. 1995. PMID: 7495923

6

Effects of psychotropic drugs on cell proliferation and differentiation.

Nordenberg J, Fenig E, Landau M, Weizman R, Weizman A. Nordenberg J, et al. Among authors: weizman r, weizman a. Biochem Pharmacol. 1999 Oct 15;58(8):1229-36. doi: 10.1016/s0006-2952(99)00156-2. Biochem Pharmacol. 1999. PMID: 10487524

7

High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome.

Hermesh H, Manor I, Shiloh R, Aizenberg D, Benjamini Y, Munitz H, Weizman A. Hermesh H, et al. Among authors: weizman a. J Clin Psychopharmacol. 2002 Jun;22(3):252-6. doi: 10.1097/00004714-200206000-00004. J Clin Psychopharmacol. 2002. PMID: 12006894

8

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.

Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A. Poyurovsky M, et al. Among authors: weizman a. Am J Psychiatry. 2002 Jun;159(6):1058-60. doi: 10.1176/appi.ajp.159.6.1058. Am J Psychiatry. 2002. PMID: 12042201 Clinical Trial.

9

Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study.

Lubin G, Weizman A, Shmushkevitz M, Valevski A. Lubin G, et al. Among authors: weizman a. Hum Psychopharmacol. 2002 Jun;17(4):181-5. doi: 10.1002/hup.395. Hum Psychopharmacol. 2002. PMID: 12404685 Clinical Trial.

10

Sexual function and behavior in social phobia.

Bodinger L, Hermesh H, Aizenberg D, Valevski A, Marom S, Shiloh R, Gothelf D, Zemishlany Z, Weizman A. Bodinger L, et al. Among authors: weizman a. J Clin Psychiatry. 2002 Oct;63(10):874-9. doi: 10.4088/jcp.v63n1004. J Clin Psychiatry. 2002. PMID: 12416596

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results